Head-To-Head Analysis: Aceto Corporation (ACET) and The Competition
Aceto Corporation (NASDAQ: ACET) is one of 113 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Aceto Corporation to similar companies based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.
Earnings & Valuation
This table compares Aceto Corporation and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aceto Corporation||$638.32 million||$68.18 million||32.09|
|Aceto Corporation Competitors||$7.79 billion||$2.46 billion||0.86|
Aceto Corporation’s rivals have higher revenue and earnings than Aceto Corporation. Aceto Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Aceto Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aceto Corporation Competitors||-3,611.17%||-54.53%||-9.08%|
Volatility and Risk
Aceto Corporation has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Aceto Corporation’s rivals have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.
Aceto Corporation pays an annual dividend of $0.26 per share and has a dividend yield of 2.3%. Aceto Corporation pays out 74.3% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.4% and pay out 82.4% of their earnings in the form of a dividend.
This is a breakdown of current recommendations for Aceto Corporation and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aceto Corporation Competitors||950||3811||6046||164||2.49|
Aceto Corporation presently has a consensus target price of $18.00, indicating a potential upside of 60.28%. As a group, “Pharmaceuticals” companies have a potential upside of 25.13%. Given Aceto Corporation’s higher possible upside, equities analysts clearly believe Aceto Corporation is more favorable than its rivals.
Insider and Institutional Ownership
82.3% of Aceto Corporation shares are held by institutional investors. Comparatively, 43.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.1% of Aceto Corporation shares are held by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Aceto Corporation beats its rivals on 8 of the 15 factors compared.
Aceto Corporation Company Profile
Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products. The Company’s business is organized along product lines into three segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. As of June 30, 2016, it distributed over 1,100 chemical compounds used primarily as finished products or raw materials in the agricultural, coatings and industrial chemical industries. The Human Health segment includes finished dosage form generic drugs and nutraceutical products. As of June 30, 2016, the Pharmaceutical Ingredients segment had two product groups: Active Pharmaceutical Ingredients and Pharmaceutical Intermediates. The Performance Chemicals segment includes specialty chemicals and agricultural protection products.
Receive News & Ratings for Aceto Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.